Your browser doesn't support javascript.
loading
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.
Rocha, Juliana Mendes; Reis, José A S; Bouso, José Carlos; Hallak, Jaime E C; Dos Santos, Rafael G.
Afiliação
  • Rocha JM; Department of Neuroscience and Behavior, Faculdade de Medicina de Ribeirão Preto, RibeirãoPreto Medical School, University of São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, SP, Brazil.
  • Reis JAS; Department of Neuroscience and Behavior, Faculdade de Medicina de Ribeirão Preto, RibeirãoPreto Medical School, University of São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, SP, Brazil.
  • Bouso JC; Department of Neuroscience and Behavior, Faculdade de Medicina de Ribeirão Preto, RibeirãoPreto Medical School, University of São Paulo, Hospital das Clínicas, Terceiro Andar, Av. Bandeirantes, 3900, Ribeirão Preto, São Paulo, SP, Brazil.
  • Hallak JEC; International Center for Ethnobotanical Education, Research, and Service (ICEERS), Barcelona, Spain.
  • Dos Santos RG; Department of Psychology and Research Center for Behavior Assessment (CRAMC), Universitat Rovira i Virgili, Tarragona, Spain.
Eur Arch Psychiatry Clin Neurosci ; 273(7): 1527-1542, 2023 Oct.
Article em En | MEDLINE | ID: mdl-36947216
Ibogaine is a psychoactive alkaloid derived from the west-African shrub Tabernanthe iboga. Western cultures are increasing the interest for the substance due to its claimed anti addictive properties, although the evidence supporting this effect is still preliminary. The use of ibogaine often occurs with no medical supervision in uncontrolled settings, and its use has been associated with several reports of severe adverse events. This review aims to evaluate the clinical studies of ibogaine, with a focus on administration settings, to elucidate specific criteria that may promote safer contexts for ibogaine use. A systematic review of the literature was conducted based on PRISMA guidelines. PubMed, Scielo, ClinicalTrials.gov and Core.ac.uk electronic databases were searched, and clinical studies published until November 17, 2022, were retrieved. The final synthesis included 12 sources. Information about general characteristics of the studies, adverse effects, screening of participants and setting characteristics were summarized and discussed. It is concluded that the use of controlled settings, supported by trained professionals and equipment allowing for rigorous medical, psychiatric, and cardiac monitoring, are essential to promote the safety of patients receiving ibogaine.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comportamento Aditivo / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Ibogaína Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Eur Arch Psychiatry Clin Neurosci Assunto da revista: NEUROLOGIA / PSIQUIATRIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comportamento Aditivo / Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos / Ibogaína Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Eur Arch Psychiatry Clin Neurosci Assunto da revista: NEUROLOGIA / PSIQUIATRIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Brasil País de publicação: Alemanha